Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: There is a significant need for novel, safe, and efficacious topical treatments for psoriasis. Objective: We assessed the safety and efficacy of tapinarof in a new cream formulation at 2 concentrations and with 2 application frequencies in adults with psoriasis. Methods: Double‐blind, vehicle‐controlled, randomized, 6‐arm trial (1:1:1:1:1:1) in adults, with psoriasis with body surface involvement ≥1% and ≤15% and Physician Global Assessment (PGA) score ≥2 at baseline. Primary endpoint included PGA of 0 or 1 at week 12 and a 2‐grade improvement from baseline. Additional analyses included assessment of ≥75% improvement of Psoriasis Area and Severity Index and mean percent change in Psoriasis Area and Severity Index and body surface area involvement. Results: Treatment success defined by PGA 0 or 1 and a 2‐grade improvement at week 12 was statistically significantly higher (at a .05 significance level) in the tapinarof groups (65% [1% twice daily], 56% [1% once daily], 46% [0.5% twice daily], and 36% [0.5% once daily]) than in the vehicle groups (11% [twice daily] and 5% [once daily]) and was maintained for 4 weeks posttreatment. Treatment‐emergent adverse events were more frequent in patients treated with tapinarof (85/152, 56%) than vehicle (19/75, 25%) and mild‐to‐moderate in intensity. Severe treatment‐emergent adverse events were reported in all tapinarof groups except the 0.5% once daily group. Limitations: Large confirmation trials are needed. Conclusions: Tapinarof cream is efficacious and well tolerated in adult patients with psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans.
Smith, S. H., Jayawickreme, C., Rickard, D. J., Nicodeme, E., Bui, T., Simmons, C., Coquery, C. M., Neil, J., Pryor, W. M., Mayhew, D., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.004 · Cited by 387
Activation of the Aryl Hydrocarbon Receptor Dampens the Severity of Inflammatory Skin Conditions
Di Meglio, P., Duarte, J. H., Ahlfors, H., Owens, N. D. L., Li, Y., Villanova, F., Tosi, I., Hirota, K., Nestle, F. O., Mrowietz, U., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.019 · Cited by 373 · cited 2×
“Patients permanently discontinued treatment due to TEAEs 5 (13) 5 (13) 4 (11) 1 (3) 0 1 (3) 16 (7)”
Bissonnette, R., Poulin, Y., Zhou, Y., Tan, J., Hong, H. C., Webster, J., Ip, W., Tang, L., & Lyle, M. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10775.x · Cited by 92
Self-citation
Cited by
Furue, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155382 · Cited by 419
New Treatment Addressing the Pathogenesis of Psoriasis
Tokuyama, M., & Mabuchi, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207488 · Cited by 291
Tryptophan Metabolism as a Pharmacological Target
Modoux, M., Rolhion, N., Mani, S., & Sokol, H. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.006 · Cited by 284
Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis
Furue, M., Hashimoto-Hachiya, A., & Tsuji, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215424 · Cited by 215
“The most commonly (≥5%) reported adverse events that emerged after treatment were folliculitis (19/152, 13% tapinarof groups and 1/75, 1% vehicle groups) and contact dermatitis (12/152, 8% only in the tapinarof groups) [22].”
BackgroundPhase 3 Trials of Tapinarof Cream for Plaque Psoriasis
Lebwohl, M. G., Stein Gold, L., Strober, B., Papp, K. A., Armstrong, A. W., Bagel, J., Kircik, L., Ehst, B., Hong, H. C.-H., Soung, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103629 · Cited by 197
Self-citationBissonnette, R., Stein Gold, L., Rubenstein, D. S., Tallman, A. M., & Armstrong, A. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.10.085 · Cited by 181
Self-citationThe aryl hydrocarbon receptor and the gut–brain axis
Barroso, A., Mahler, J. V., Fonseca-Castro, P. H., & Quintana, F. J. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00585-5 · Cited by 152
Stein Gold, L., Bhatia, N., Tallman, A. M., & Rubenstein, D. S. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.181 · Cited by 48
Kim, J. E., Kim, H. R., Kang, S. Y., Jung, M. J., Heo, N. H., Lee, H. J., Ryu, A., Kim, H. O., Park, C. W., & Chung, B. Y. (2021) · Annals of Dermatology · doi:10.5021/ad.2021.33.2.138 · Cited by 19
Metadata
- Authors
- Robbins, K., Bissonnette, R., Maeda-Chubachi, T., Ye, L., Peppers, J., Gallagher, K., & Kraus, J. E.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 80
- Issue
- 3
- Pages
- 714-721
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2898213950
- Cited by
- 93
- References
- 4
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.